Comment | Published:

Cause, Consequence or confounding? The kidney in hypertension

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Harlos J, Heidland A. Hypertension as cause and consequence of renal disease in the 19th century. Am J Nephrol. 1994;14:436–42.

  2. 2.

    Guyton AC. The surprising kidney-fluid mechanism for pressure control--its infinite gain! Hypertension. 1990;16:725–30.

  3. 3.

    Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005;165:923–8.

  4. 4.

    Leiba A, Fishman B, Twig G, Gilad D, Derazne E, Shamiss A, et al. Association of adolescent hypertension with future end-stage renal disease. JAMA Intern Med. 2019 Feb 25. [Epub ahead of print].

  5. 5.

    Maeda Tea. Usefulness of the blood pressure classification in the new 2017 ACC/AHA 2 hypertension guidelines for the prediction of new-onset chronic kidney disease. J Hum Hypertens. 2019. in press.

  6. 6.

    Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–e115.

  7. 7.

    Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. J Am Med Assoc. 1967;202:1028–34.

  8. 8.

    Cushman WC, Evans GW, Byington RP, Goff DC Jr., Grimm RH Jr., Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.

  9. 9.

    Wright JT Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103–16. Nov 26

  10. 10.

    Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–67.

  11. 11.

    Malhotra R, Craven T, Ambrosius WT, Killeen AA, Haley WE, Cheung AK, et al. Effects of intensive blood pressure lowering on kidney tubule injury in CKD: A Longitudinal Subgroup Analysis in SPRINT. Am J Kidney Dis. 2019;73:21–30.

  12. 12.

    Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.

  13. 13.

    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930–42.

Download references

Author information

Conflict of interest

The authors declare that they have no conflict of interest.

Correspondence to Swapnil Hiremath.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark